Life sciences and medtech names delivered a dense slate of news on Tuesday, headlined by a fresh fundraise from an oncology drug developer to fund its clinical programme, alongside a digital health group flagging accelerating revenue, an NHS diagnostics tie-up, a European device launch and two clinical-stage pharma milestones. The common thread was companies funding or validating their pipelines, capital raises, trial enrolments and regulatory wins rather than speculative moves.
Avacta raises £12.5m to push lead oncology drug through clinic
Avacta Group (AIM:AVCT) has conditionally raised gross proceeds of £12.5m through a placing of 17.41m new shares and a subscription for 970,587 new shares, both priced at 68p, with the stock trading at 67.5p, down 6.25%, as the dilution was digested. The life sciences company, developing targeted oncology drugs through its pre|CISION platform, set the issue price at a roughly 5.6% discount to the 72p closing mid-market price on 29 September, the last trading day before the capital access window opened. The new shares represent approximately 3.9% of Avacta's existing issued share capital.
Four non-executive directors took part in the subscription tranche, investing roughly £660,000 in aggregate: Non-Executive Chairman Richard Hughes subscribed £500,000 for 735,294 shares, Non-Executive Deputy Chairman Patrick Vink put in £75,000, Non-Executive Director David Bryant subscribed £50,000 and Non-Executive Director Mats Blom subscribed £35,000. The raise follows a £9m placing in June at 70p a share used to repay deferred convertible bond instalments, and a £10m placing in March that extended Avacta's cash runway into early 2027, taking total gross proceeds over the prior eighteen months to approximately £41.5m. The company also settled a further £3.67m accelerated amortisation payment on the convertible bond in July following a bondholder acceleration notice, cutting the remaining principal to £16.8m.
"with the delivery of the first data showing the controlled-release mechanism is working in patients precisely as intended," said Christina Coughlin, chief executive of Avacta.
The repeated recourse to equity markets, three raises in eighteen months totalling over £54m once this placing is included, underscores how capital-intensive Avacta's path to commercialisation remains, even as the clinical data itself has moved in the company's favour. AVA6103 achieving clinical proof of mechanism in the Phase 1 FOCUS-01 trial in September, with patients now dosed at dose level four and first efficacy data emerging, gives the company a genuine scientific catalyst to point to. But insiders backing the subscription alongside new money signals confidence in the mechanism rather than removing the underlying question of when, or whether, Avacta reaches self-funding status before the convertible bond and future raises further dilute existing holders.
Cambridge Cognition joins NHS study on earlier Alzheimer's diagnosis
Cambridge Cognition Holdings (AIM:COG), trading at 28.0p, is joining BEAD-PC, a UK study led by Imperial College London that will test combining its CANTAB digital cognitive assessments with blood-based biomarkers to diagnose Alzheimer's disease in primary care. The neuroscience technology company's assessments are already used extensively in clinical trials and academic research, and this deal extends that validated technology into a live NHS diagnostic pathway rather than a purely research setting.
Initiated in June and running for 15 months, BEAD-PC aims to recruit 500 participants with subjective memory complaints or early cognitive decline symptoms across North West London, with GPs referring eligible patients to dedicated Primary Care Assessment Centres for digital cognitive testing and blood sampling. The study forms part of the Davos Alzheimer's Collaborative's Healthcare System Preparedness Accurate Diagnosis programme, a global initiative also running in the United States, Germany, the Netherlands and Japan.
For Cambridge Cognition, the tie-up offers a route from academic validation toward real-world NHS deployment, the kind of pathway that could underpin future procurement conversations if BEAD-PC demonstrates that CANTAB plus blood biomarkers can meaningfully shorten the diagnostic journey for memory-complaint patients moving through primary care.
MedPal AI revenue run rate boosted by repeat orders
MedPal AI (AIM:MPAL), the AI-native digital health and pharmacy group, reported further revenue growth in September alongside a notice to shareholders of a general meeting to renew its share issuance authorities, even as the stock fell 17.03% to 5.7p. Group annualised revenue run rate rose to more than £38m, up from more than £35m reported on 21 September and approximately £28m in August, a figure the company calculates by multiplying September revenue by twelve rather than forecasting.
New Health, the group's consumer GLP-1 weight-management brand, generated revenue of more than £2.7m in September, up approximately 50% on August's £1.8m, from over 22,600 orders. The month accelerated as it progressed: daily revenue in the final eleven days ran approximately 50% higher than in the first nineteen, finishing well ahead of the pace the company had flagged two weeks earlier. More than £1m of September's revenue came from New Health repeat orders, NHS prescriptions and eMARx. "New Health grew revenue by approximately 50% in September and finished the month well ahead of the pace we reported two weeks ago, contributed over £1 million, around a third of the month," said Jason Drummond, founder of MedPal AI.
The sharp share price fall against an improving revenue trajectory highlights a disconnect investors will need reconciling, the growth numbers point to genuine commercial traction in the GLP-1 and repeat-order business, while the looming general meeting to renew issuance authorities raises the prospect of further dilution that the market appears to be pricing in ahead of time.
Smith+Nephew brings cartilage repair implant to Europe
Smith+Nephew (LSE:SN.), the London and New York-listed medical technology group, said its CARTIHEAL AGILI-C Cartilage Repair Implant is now commercially available in Europe, with shares at 1002.5p, down 0.5% on the day. The device will be showcased at the International Cartilage Regeneration & Joint Preservation Society Summit in Porto, Portugal, running from 8 to 10 October, having first launched in the United States in 2024 as part of the group's sports medicine push to widen access to cartilage repair procedures for patients who previously had none.
The implant is made from aragonite, a naturally occurring calcium carbonate that acts as a biphasic scaffold, designed to repair cartilage, restore bone and relieve pain. A multicentre, randomised controlled trial published in the American Journal of Sports Medicine found the implant delivered higher Knee injury and Osteoarthritis Outcome Scores than surgical standard of care, comparing it against microfracture or debridement. "The launch of the CARTIHEAL Implant in Europe brings surgeons an innovative, evidence-backed solution for cartilage repair and reinforces our focus on helping patients achieve better long-term outcomes and return to their active lives," said Joaquin Lasso, president of Sports Medicine International at Smith+Nephew.
Extending a US-proven device into the European market widens the addressable patient population for a procedure category where treatment options have historically been, giving Smith+Nephew another lever in its sports medicine franchise as it looks to diversify growth beyond its core orthopaedics and wound care businesses.
Poolbeg Pharma secures South Korean patent for POLB 001
Poolbeg Pharma (AIM:POLB) has been granted a patent in South Korea covering POLB 001, its IL-6 receptor antagonist in development, with shares rising 3.0% to 7.21p on the news. The grant extends the company's intellectual property protection into a significant Asian pharmaceutical market, adding to its existing patent estate for the asset.
Securing patent coverage in South Korea strengthens Poolbeg's negotiating position with potential licensing or development partners in the region, reinforcing the commercial value of POLB 001 ahead of any future out-licensing discussions for the programme.
OKYO Pharma enrolls first patients in Phase 3 neuropathic corneal pain trial
OKYO Pharma has enrolled its first patients in a Phase 3 trial evaluating its lead candidate in neuropathic corneal pain, moving the programme into late-stage development. The milestone marks a step change in the company's clinical risk profile as it advances toward the kind of pivotal data that could support a future regulatory submission.
Neuropathic corneal pain remains a condition with few approved treatment options, and successful completion of this Phase 3 study would position OKYO's candidate as a potential first-in-class therapy, a prospect that underpins much of the investment case for the company as it works through late-stage trial execution.